NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

Under the category of how this kind of news can influence transactions, competition in the oncology space may make it difficult to value Direct. So it’s very possible — certainly feasible— there’s a spinoff to form a pure-play DCVax partnership, leaving NWBO as the developer of Direct. Perhaps with Merck having hands in both pockets.

L is too far advanced to having any near term competition, and there’s plenty of space for new entrants given that treatments for GBM will likely require many tools in the tool box.